A few years back, French President Sarkozy requested an assessment of his country’s biomedical research. The eminent scientists who conducted it concluded that, while some of it was cutting-edge – as evidenced by French scientists’ contributions to the PCSK9 and CRISPR discoveries – quite a bit of it was mundane and not generating great value. So they recommended that the labs and research institutes with a good innovation record receive a greater share of the funding so that they could do more good. Not in France, they were told. The country’s egalitarian values, which are proudly displayed on the façade of many of its Town Halls, demanded that the money be distributed evenly, without regard to performance.